Determining intestinal metaplasia and dysplasia in obese patients candidate for surgery

Gastric mapping for intestinal metaplasia and dysplasia in morbid obese patients candidate for bariatric surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201305204811N3

Enrollment

174

Registered

2015-05-23

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Obesity and sleep apnea. Condition 2: Obesity. Condition 3: all types of obesity. Condition 4: Morbid obesity. Extreme obesity with alveolar hypoventilation Obesity due to excess calories Simple obesity NOS Morbid obesity

Interventions

All patients who sign an informed consent form will be endoscopically evaluated and gastric biopsy will be done. CBC, platelet, ESR, CRP, FBS, TG, Chol, HDL, and LDL will also be determined after taki

Diagnosis

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Morbid obese patients (BMI > 35 kg/m2), aged between 18 and 70 years old who are not involved in any other interventional study, have tendency for doing upper endoscopy and gastric biopsy. Exclusion criteria: Cases with any severe diseases of kidney and heart and any other end stage diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Gastric dysplasia. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Mucosal atrophy. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;H. pylori infection. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Gastric metaplasia. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Chronic gastritis. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Reactive atypia of glandular epithelium. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.	—

Measure

Time frame

Gastric dysplasia. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Mucosal atrophy. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;H. pylori infection. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Gastric metaplasia. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Chronic gastritis. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.;Reactive atypia of glandular epithelium. Timepoint: At the beginning of study. Method of measurement: gastric biopsy.

—

Secondary

Measure	Time frame
FBS. Timepoint: at the beginning of study. Method of measurement: ELISA.;TG. Timepoint: at the beginning of study. Method of measurement: ELISA.;Total Cholestrol, LDL, HDL. Timepoint: at the beginning of study. Method of measurement: ELISA.;CRP, ESR. Timepoint: at the beginning of study. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Kabir

Iran University of Medical Sciences

aikabir@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026